Substantial doubt about the company's ability to continue as a going concern.
“Based on the above matters, we have concluded that there is substantial doubt regarding the Company's ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Nasdaq notified Actuate Therapeutics, Inc. that its closing bid price remained below $1.00 per share for the last 30 consecutive business days. The company has until April 26, 2027 to regain compliance.
Actuate Therapeutics closed an offering on October 28, 2026, issuing 30,985,900 common shares and warrants for 15,492,950 shares, generating approximately $9.96 million net proceeds; the warrants have a $0.45 exercise price and expire five years after issuance.
Actuate Therapeutics is offering 40,000,000 shares of common stock with accompanying purchase warrants and pre-funded warrants at an assumed combined price of $1.00 per two shares and warrant, with Newbridge Securities as sole book-running manager and a 45-day over-allotment option.
Actuate Therapeutics, Inc. proposes to sell 65,000,000 common shares at an assumed $0.6437 per share. The underwriter has a 45-day option for up to 9,750,000 additional shares, potentially increasing the offering to 74,750,000 shares.
Actuate Therapeutics, Inc. is offering 50,000,000 shares of common stock at an assumed $0.819 per share. Its mPDAC study met its primary endpoint, improving median overall survival to 10.1 months from 7.2 months (p=0.02, HR=0.62).
